PL393155A1 - Pochodne fenetanoloaminy do leczenia chorób układu oddechowego - Google Patents

Pochodne fenetanoloaminy do leczenia chorób układu oddechowego

Info

Publication number
PL393155A1
PL393155A1 PL393155A PL39315502A PL393155A1 PL 393155 A1 PL393155 A1 PL 393155A1 PL 393155 A PL393155 A PL 393155A PL 39315502 A PL39315502 A PL 39315502A PL 393155 A1 PL393155 A1 PL 393155A1
Authority
PL
Poland
Prior art keywords
treating
respiratory diseases
phenethanolamine derivatives
phenethanolamine
derivatives
Prior art date
Application number
PL393155A
Other languages
English (en)
Polish (pl)
Inventor
Philip Charles Box
Diane Mary Coe
Brian Edgar Looker
Panaviotis Alexandrou Procopiou
Inderij Singh Mann
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0122201A external-priority patent/GB0122201D0/en
Priority claimed from GB0126997A external-priority patent/GB0126997D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of PL393155A1 publication Critical patent/PL393155A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/76—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and etherified hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/38—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL393155A 2001-09-14 2002-09-11 Pochodne fenetanoloaminy do leczenia chorób układu oddechowego PL393155A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0122201A GB0122201D0 (en) 2001-09-14 2001-09-14 Medicinal compounds
GB0126997A GB0126997D0 (en) 2001-11-09 2001-11-09 Medicinal Compounds

Publications (1)

Publication Number Publication Date
PL393155A1 true PL393155A1 (pl) 2011-03-28

Family

ID=26246542

Family Applications (2)

Application Number Title Priority Date Filing Date
PL393155A PL393155A1 (pl) 2001-09-14 2002-09-11 Pochodne fenetanoloaminy do leczenia chorób układu oddechowego
PL370276A PL211953B1 (pl) 2001-09-14 2002-09-11 Pochodna fenetanoloaminy, zawierający ją środek farmaceutyczny i zastosowanie pochodnej fenetanoloaminy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL370276A PL211953B1 (pl) 2001-09-14 2002-09-11 Pochodna fenetanoloaminy, zawierający ją środek farmaceutyczny i zastosowanie pochodnej fenetanoloaminy

Country Status (31)

Country Link
US (6) US7361787B2 (en:Method)
EP (2) EP1425001B1 (en:Method)
JP (1) JP4191034B2 (en:Method)
KR (2) KR20090057477A (en:Method)
CN (3) CN101701006B (en:Method)
AR (2) AR036874A1 (en:Method)
AT (1) ATE417606T1 (en:Method)
AU (1) AU2002326026B2 (en:Method)
BE (1) BE2014C026I2 (en:Method)
BR (1) BRPI0212455B8 (en:Method)
CA (1) CA2458534C (en:Method)
CO (1) CO5560552A2 (en:Method)
CY (3) CY1109422T1 (en:Method)
DE (1) DE60230425D1 (en:Method)
DK (2) DK2042168T3 (en:Method)
ES (2) ES2316599T3 (en:Method)
FR (1) FR14C0028I2 (en:Method)
HU (2) HU228508B1 (en:Method)
IL (2) IL160595A0 (en:Method)
LT (1) LTC1425001I2 (en:Method)
LU (1) LU92439I2 (en:Method)
MX (1) MXPA04002405A (en:Method)
MY (1) MY129422A (en:Method)
NO (2) NO333813B1 (en:Method)
NZ (1) NZ531651A (en:Method)
PL (2) PL393155A1 (en:Method)
PT (2) PT2042168E (en:Method)
RU (2) RU2312854C2 (en:Method)
SI (2) SI1425001T1 (en:Method)
TW (1) TWI299661B (en:Method)
WO (1) WO2003024439A1 (en:Method)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
CN101701006B (zh) 2001-09-14 2014-03-05 葛兰素集团有限公司 治疗呼吸疾病的苯乙醇胺衍生物
AU2002333644A1 (en) 2001-09-17 2003-04-01 Glaxo Group Limited Dry powder medicament formulations
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
AU2003239880A1 (en) 2002-05-28 2003-12-12 Theravance, Inc. ALKOXY ARYL Beta2 ADRENERGIC RECEPTOR AGONISTS
GB0220730D0 (en) * 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
DK1556342T3 (da) 2002-10-28 2008-07-21 Glaxo Group Ltd Phenethanolaminderivat til behandling af respiratoriske sygdomme
GB0303396D0 (en) * 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US7060712B2 (en) 2003-05-08 2006-06-13 Theravance, Inc. Crystalline form of aryl aniline β2 adrenergic receptor agonist
TW200510277A (en) 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
US7067541B2 (en) 2003-06-04 2006-06-27 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
ES2298757T3 (es) * 2003-06-04 2008-05-16 Pfizer Inc. Derivados de z-amino-piridina como agonistas de adrecorreceptores beta-2.
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
GB0329182D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
WO2005121065A2 (en) 2004-06-03 2005-12-22 Theravance, Inc. DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
WO2006014704A1 (en) 2004-07-21 2006-02-09 Theravance, Inc. DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
US7569586B2 (en) 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP2008512470A (ja) * 2004-09-10 2008-04-24 セラヴァンス， インコーポレーテッド アミジン置換アリールアニリン化合物
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
ATE517908T1 (de) 2005-01-10 2011-08-15 Glaxo Group Ltd Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
UY29440A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
US7994211B2 (en) 2005-08-08 2011-08-09 Argenta Discovery Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
GB0520794D0 (en) * 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
KR20130020850A (ko) 2005-10-21 2013-02-28 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
AR058109A1 (es) 2005-12-20 2008-01-23 Glaxo Group Ltd Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
MX2008013411A (es) 2006-04-20 2008-11-04 Glaxo Group Ltd Nuevos compuestos.
AR060607A1 (es) 2006-04-21 2008-07-02 Novartis Ag Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias.
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
TW200817006A (en) 2006-06-23 2008-04-16 Smithkline Beecham Corp IL-8 receptor antagonist
WO2008015416A1 (en) 2006-08-01 2008-02-07 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
DE602007011670D1 (de) 2007-01-10 2011-02-10 Irm Llc Verbindungen und zusammensetzungen als kanal-aktivierende proteasehemmer
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
MX2009008493A (es) 2007-02-09 2009-08-20 Irm Llc Compuestos y composiciones como inhibidores de la proteasa activadora de canal.
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
ES2361595T3 (es) 2007-05-07 2011-06-20 Novartis Ag Compuestos orgánicos.
WO2009074575A2 (en) 2007-12-10 2009-06-18 Novartis Ag Organic compounds
PL2231642T3 (pl) 2008-01-11 2014-04-30 Novartis Ag Pirymidyny jako inhibitory kinazy
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
EA019819B1 (ru) 2008-05-23 2014-06-30 ПАНМИРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Кристаллическая полиморфная форма с ингибитора белка, активирующего 5-липоксигеназу, фармацевтическая композиция на ее основе и применение в лечении
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
CN102112130A (zh) 2008-06-10 2011-06-29 诺瓦提斯公司 作为上皮钠通道阻滞剂的吡嗪衍生物
MX2010013477A (es) 2008-06-18 2010-12-21 Astrazeneca Ab Derivados de benzoxazinona que actuan como agonistas de receptores adrenergicos beta2 para el tratamiento de trastornos respiratorios.
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
JP5555255B2 (ja) 2008-12-30 2014-07-23 プルマゲン セラピューティクス（インフラメーション）リミテッド 呼吸器疾患の治療のためのスルホンアミド化合物
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
HUE067290T2 (hu) 2009-02-26 2024-10-28 Glaxo Group Ltd 4-{(1 R)-2-[(6-{2-[(2,6-diklórbenzil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroxi-metil)fenolt tartalmazó gyógyszerkészítmények
WO2010097114A1 (en) * 2009-02-26 2010-09-02 Glaxo Group Limited Novel combination of therapeutic agents
ES2542551T3 (es) 2009-03-09 2015-08-06 Glaxo Group Limited 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
US20120058984A1 (en) 2009-03-17 2012-03-08 Catherine Mary Alder Pyrimidine derivatives used as itk inhibitors
WO2010107958A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520685A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＧＡＴＡ結合タンパク質３（ＧＡＴＡ３）遺伝子発現のＲＮＡ干渉媒介性阻害
CA2755773A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina)
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
KR20110138223A (ko) 2009-03-27 2011-12-26 머크 샤프 앤드 돔 코포레이션 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
EP2411520A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120010272A1 (en) 2009-03-27 2012-01-12 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012524754A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド Ｃｒａｃチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
US8399436B2 (en) 2009-04-24 2013-03-19 Glaxo Group Limited N-pyrazolyl carboxamides as CRAC channel inhibitors
UY32585A (es) 2009-04-30 2010-11-30 Glaxo Group Ltd Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
EP2453894B1 (en) 2009-07-15 2015-11-04 Theravance Biopharma R&D IP, LLC Crystalline freebase form of a biphenyl compound
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
US20120238571A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Indazole derivatives as pi 3-kinase
EP2507223A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
WO2011084316A2 (en) 2009-12-16 2011-07-14 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
KR101004750B1 (ko) * 2010-08-16 2011-01-04 주식회사 행림종합 건축사사무소 피막보호형 보강 단열패널 및 이를 이용한 노출형 외단열방수공법
EP2954888A1 (en) 2010-08-31 2015-12-16 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
AU2014268195B2 (en) * 2010-08-31 2015-11-12 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
PT2614058E (pt) 2010-09-08 2015-10-27 Glaxosmithkline Ip Dev Ltd Polimorfos e sais de n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4- morfolinil]metil}-1,3-oxazol-2-il)-1h-indazol-6-il]-2- (metiloxi)-3-piridinil]metanossulfonamida
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
JP5795643B2 (ja) 2010-10-21 2015-10-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物
EP2630127A1 (en) 2010-10-21 2013-08-28 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
KR20140012989A (ko) 2011-02-17 2014-02-04 시플라 리미티드 글리코피롤레이트 및 베타2-효능제의 조합
PH12013501758A1 (en) 2011-02-25 2013-10-14 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
EP2683716A1 (en) 2011-03-11 2014-01-15 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
BR112013031570A2 (pt) 2011-06-08 2017-03-21 Glaxo Group Ltd inalador de pó seco.
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
JP5886433B2 (ja) 2011-09-16 2016-03-16 ノバルティス アーゲー 嚢胞性線維症処置のためのヘテロ環式化合物
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
GB201116641D0 (en) 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CA2869849A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
GB201207406D0 (en) 2012-04-27 2012-06-13 Glaxo Group Ltd Novel compounds
AR090847A1 (es) 2012-04-27 2014-12-10 Glaxo Group Ltd Compuestos moduladores del receptor huerfano retinoideo (ror)
WO2014007768A1 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhaler compositions comprising long acting muscorinic antagonists
US20150239862A1 (en) * 2012-09-13 2015-08-27 Perrigo Api Ltd. Process for the preparation of vilanterol and intermediates thereof
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
PL2968313T3 (pl) 2013-03-15 2018-07-31 Verona Pharma Plc Kombinacja leków
US20160256466A1 (en) 2013-10-17 2016-09-08 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
EP3057588A1 (en) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CN104744271B (zh) * 2013-12-26 2016-08-31 成都伊诺达博医药科技有限公司 一种合成维兰特罗的新工艺
CN104744270A (zh) * 2013-12-26 2015-07-01 成都伊诺达博医药科技有限公司 长效β2受体激动剂维兰特罗的合成新方法
CN106458980A (zh) 2014-04-24 2017-02-22 诺华股份有限公司 作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物
MX2016013983A (es) 2014-04-24 2017-04-06 Novartis Ag Derivados de pirazina como inhibidores de fosfatidil-inositol-3-ci nasa.
JP6433509B2 (ja) 2014-04-24 2018-12-05 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのアミノピラジン誘導体
MX2016014859A (es) 2014-05-12 2017-06-27 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas.
EP4252742A3 (en) 2014-05-28 2023-12-27 GlaxoSmithKline Intellectual Property Development Ltd Fluticasone furoate in the treatment of copd
EP2957553A1 (en) 2014-06-16 2015-12-23 Arven Ilac Sanayi Ve Ticaret A.S. Pharmaceutical formulations of vilanterol
EP2957552B1 (en) 2014-06-16 2020-01-22 Arven Ilac Sanayi Ve Ticaret A.S. Vilanterol formulations
MA39288A (fr) 2014-06-16 2015-12-23 Arven Ilac Sanayi Ve Ticaret As Formulations pharmaceutiques comprenant du vilanterol
TR201407010A2 (tr) 2014-06-16 2015-12-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Vilanterol formülasyonları.
WO2016005443A1 (en) 2014-07-09 2016-01-14 Arven Ilac Sanayi Ve Ticaret A.S. A process for the preparation of formulations for inhalation
ES2672383T3 (es) 2014-07-09 2018-06-14 Arven Ilac Sanayi Ve Ticaret A.S. Un procedimiento de preparación de las formulaciones de inhalación
EP3166592A1 (en) 2014-07-09 2017-05-17 Arven Ilac Sanayi Ve Ticaret A.S. A process for the preparation of dry powder formulations
WO2017001907A1 (en) 2015-06-29 2017-01-05 Teva Pharmaceuticals International Gmbh Biocatalytic processes for the preparation of vilanterol
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN107188813B (zh) * 2016-03-14 2019-04-26 益方生物科技（上海）有限公司 苯乙醇胺衍生物及其制备方法和用途
WO2018029126A1 (en) 2016-08-08 2018-02-15 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
PT110209B (pt) * 2017-07-19 2021-05-17 Hovione Farm Sa Formas polimórficas de trifenatato de vilanterol e processos para a preparação das mesmas.
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3766866B1 (en) 2018-03-14 2023-10-25 Asahi Kasei Kabushiki Kaisha Method for producing sulfonic-acid-group-containing monomer
IT201800004492A1 (it) * 2018-04-13 2019-10-13 Procedimento per la sintesi di beta-amminoalcoli otticamente attivi
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
FR3085834B1 (fr) 2018-09-14 2022-04-29 Euroteknika Systeme d'implants dentaire
CN109574861A (zh) * 2019-01-22 2019-04-05 安徽德信佳生物医药有限公司 一种维兰特罗三苯乙酸盐的结晶方法
CN111807973B (zh) * 2019-04-10 2021-04-30 上海谷森医药有限公司 维兰特罗及其盐的制备方法
WO2020237151A1 (en) 2019-05-23 2020-11-26 Huang Cai Gu Inhalable formulation of a solution containing vilanterol trifenatate and umeclidinium bromide
CN113891744A (zh) 2019-06-10 2022-01-04 诺华股份有限公司 用于治疗cf、copd和支气管扩张的吡啶和吡嗪衍生物
BR112022002569A2 (pt) 2019-08-28 2022-07-19 Novartis Ag Derivados de 1,3-fenil heteroarila substituídos e seu uso no tratamento de doenças
WO2021150471A1 (en) 2020-01-20 2021-07-29 Huang Cai Gu Liposome formulation of vilanterol trifenatate
WO2022023291A1 (en) 2020-07-27 2022-02-03 Inke, S.A. Method for the purification of vilanterol trifenatate
WO2023118833A1 (en) 2021-12-22 2023-06-29 Hovione Scientia Limited Process to prepare vilanterol trifenatate
CN115286491B (zh) * 2022-08-31 2023-09-15 山东省药学科学院 一种2-[2-(6-溴己氧基)乙氧基甲基]-1,3-二氯苯的制备方法
CN117679423A (zh) 2022-09-05 2024-03-12 立生医药(苏州)有限公司 预防或治疗呼吸系统疾病的吸入用药物组合物
CN115745945B (zh) * 2022-11-15 2024-06-11 奥锐特药业股份有限公司 一锅法制备维兰特罗中间体的方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2140800A (en) * 1937-04-26 1938-12-20 Metallurg De Hoboken Soc Gen Treatment of substances containing tantalum and/or niobium
US2918408A (en) 1957-04-08 1959-12-22 Lakeside Lab Inc Anti-spasmodic compositions specific for treating spasm of the colon
DE2140800C3 (de) 1971-08-14 1980-10-16 Industriewerk Schaeffler Ohg, 8522 Herzogenaurach Loswalze für Streckwerke von Spinnmaschinen
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
US4627432A (en) 1982-10-08 1986-12-09 Glaxo Group Limited Devices for administering medicaments to patients
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
NZ211822A (en) * 1984-04-17 1988-11-29 Glaxo Group Ltd Phenethanolamine derivatives and pharmaceutical compositions
DK173685A (da) 1984-04-17 1985-10-18 Glaxo Group Ltd Ethanolaminderivater
US4853381A (en) * 1984-04-17 1989-08-01 Glaxo Group Limited Ethanolamine compounds
GB8426200D0 (en) 1984-10-17 1984-11-21 Glaxo Holdings Ltd Chemical compounds
IL75794A (en) 1984-07-13 1989-01-31 Glaxo Group Ltd 2-hydroxy-5-(1-hydroxy-2-(aralkyloxyalkylamino)ethyl)aniline derivatives,their preparation and pharmaceutical compositions containing them
FI88112C (fi) 1985-07-30 1993-04-13 Glaxo Group Ltd Anordning foer administrering av laekemedel till patienter
FR2588474B1 (fr) 1985-10-16 1987-11-27 Cird Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste
GB8525483D0 (en) 1985-10-16 1985-11-20 Glaxo Group Ltd Chemical compounds
EP0220054A3 (en) 1985-10-16 1987-12-02 Glaxo Group Limited Ethanolamine derivatives
EP0223410A3 (en) 1985-10-16 1987-11-19 Glaxo Group Limited Ethanolamine derivatives
US4937268A (en) * 1987-03-12 1990-06-26 Glaxo Group Limited Chemical compounds
GB8718940D0 (en) 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
DK633588A (da) * 1987-11-13 1989-05-14 Glaxo Group Ltd Aminderivater
GB8821179D0 (en) * 1988-09-09 1988-10-12 Glaxo Group Ltd Chemical compounds
GB2230523A (en) 1989-04-14 1990-10-24 Glaxo Group Ltd 1-(3-Bromoisoxazol-5-yl)-2-aminoethanol derivatives
GB8909273D0 (en) 1989-04-24 1989-06-07 Glaxo Group Ltd Chemical compounds
US5290815A (en) 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
DE4028398A1 (de) 1990-09-07 1992-03-12 Thomae Gmbh Dr K Phenylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CZ283425B6 (cs) * 1992-04-02 1998-04-15 Smithkline Beecham Corporation Fenylové deriváty a farmaceutické prostředky s jejich obsahem
GB9222700D0 (en) 1992-10-29 1992-12-09 Smithkline Beecham Plc Chemical compounds
TW263495B (en:Method) * 1992-12-23 1995-11-21 Celltech Ltd
GB9313574D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Medicaments
GB9323429D0 (en) 1993-11-12 1994-01-05 Wellcome Found Therapy
AU1533495A (en) 1994-01-12 1995-08-01 Byk Nederland Bv Phenyl ethanol amine ethers and uses thereof as beta-adreno-receptor agonists
US5998428A (en) * 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
EP0947498B1 (en) 1996-12-02 2004-09-15 Chisso Corporation Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
JP2002506856A (ja) 1998-03-14 2002-03-05 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング フタラジノンｐｄｅｉｉｉ／ｉｖ阻害剤
AR035987A1 (es) 1999-03-01 2004-08-04 Smithkline Beecham Corp Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
NZ517166A (en) 1999-08-21 2004-01-30 Altana Pharma Ag Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonists
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE365720T1 (de) 2001-03-08 2007-07-15 Glaxo Group Ltd Agonisten von beta-adrenorezeptoren
CN101701006B (zh) 2001-09-14 2014-03-05 葛兰素集团有限公司 治疗呼吸疾病的苯乙醇胺衍生物
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols

Also Published As

Publication number Publication date
IL160595A (en) 2010-05-17
EP1425001B1 (en) 2008-12-17
PL211953B1 (pl) 2012-07-31
CY1109422T1 (el) 2014-08-13
ES2438985T3 (es) 2014-01-21
LU92439I2 (fr) 2014-06-30
HU228508B1 (en) 2013-03-28
AU2002326026B2 (en) 2005-04-28
PL370276A1 (en) 2005-05-16
BE2014C026I2 (en:Method) 2021-11-22
PT2042168E (pt) 2014-01-03
HK1066479A1 (en) 2005-03-24
NO2014007I1 (no) 2014-06-02
LTC1425001I2 (lt) 2025-05-26
KR20040035788A (ko) 2004-04-29
JP2005511508A (ja) 2005-04-28
BRPI0212455B8 (pt) 2021-05-25
ES2316599T3 (es) 2009-04-16
AR036874A1 (es) 2004-10-13
CN101701006B (zh) 2014-03-05
US20090068273A1 (en) 2009-03-12
US20110269970A1 (en) 2011-11-03
RU2007124187A (ru) 2009-01-10
US7776895B2 (en) 2010-08-17
KR20090057477A (ko) 2009-06-05
HUP0401619A3 (en) 2008-03-28
AR091595A2 (es) 2015-02-18
SI1425001T1 (sl) 2009-04-30
BRPI0212455B1 (pt) 2016-05-03
WO2003024439A1 (en) 2003-03-27
LTPA2014019I1 (lt) 2014-05-26
CA2458534A1 (en) 2003-03-27
US20080003290A1 (en) 2008-01-03
IL160595A0 (en) 2004-07-25
BR0212455A (pt) 2004-10-19
HUS1400025I1 (hu) 2016-08-29
MY129422A (en) 2007-03-30
US7439393B2 (en) 2008-10-21
NO20041041L (no) 2004-04-21
CY2014019I2 (el) 2015-12-09
DK2042168T3 (da) 2014-01-06
CA2458534C (en) 2011-11-01
MXPA04002405A (es) 2004-05-31
CO5560552A2 (es) 2005-09-30
US20110009631A1 (en) 2011-01-13
US8198483B2 (en) 2012-06-12
ATE417606T1 (de) 2009-01-15
CN103288793A (zh) 2013-09-11
US7361787B2 (en) 2008-04-22
NZ531651A (en) 2006-02-24
FR14C0028I1 (en:Method) 2014-05-16
FR14C0028I2 (fr) 2015-02-20
CN103288793B (zh) 2015-09-23
DK1425001T3 (da) 2009-04-14
EP2042168B1 (en) 2013-10-23
DE60230425D1 (de) 2009-01-29
JP4191034B2 (ja) 2008-12-03
HUP0401619A2 (hu) 2004-11-29
US7982067B2 (en) 2011-07-19
US20050075394A1 (en) 2005-04-07
RU2004106555A (ru) 2005-07-10
CY2014019I1 (el) 2015-12-09
NO333813B1 (no) 2013-09-23
NO2014007I2 (no) 2014-04-03
CN1585633B (zh) 2010-10-27
EP2042168A1 (en) 2009-04-01
USRE44874E1 (en) 2014-04-29
EP1425001A1 (en) 2004-06-09
CN1585633A (zh) 2005-02-23
RU2312854C2 (ru) 2007-12-20
KR100912324B1 (ko) 2009-08-14
PT1425001E (pt) 2009-02-18
CN101701006A (zh) 2010-05-05
TWI299661B (en) 2008-08-11
SI2042168T1 (sl) 2014-01-31
CY1114728T1 (el) 2016-10-05

Similar Documents

Publication Publication Date Title
PL393155A1 (pl) Pochodne fenetanoloaminy do leczenia chorób układu oddechowego
IL157149A0 (en) Phenethanolamine derivatives for treatment of respiratory diseases
PL377122A1 (pl) Pochodne fenetanoloaminy do leczenia chorób układu oddechowego
AU2003210428A1 (en) Phenethanolamine derivatives for treatment of respiratory diseases
AU2003279338A1 (en) Phenethanolamine derivatives for the treatment of respiratory diseases
AU2003291992A1 (en) Phenylethanolamine derivatives for the treatment of respiratory diseases
GB0123951D0 (en) Therapies for treating respiratory diseases
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
GB0015745D0 (en) Treatment of bone diseases
HUP0400024A3 (en) Combination for treatment of neoplastic diseases
GB0004531D0 (en) The treatment of respiratory diseases
HUP0401805A3 (en) Compounds suitable for treating pulmonary diseases
AU5937901A (en) Combination therapy of respiratory diseases using antibodies
AU2002338303A1 (en) Therapeutic compositions for the treatment of a respiratory tract disease
EP1389129A4 (en) METHOD FOR TREATING RESPIRATORY DISEASES
HK1061386A (en) Phenethanolamine derivatives for treatment of respiratory diseases
GB0100092D0 (en) Treatment of degenerative diseases
GB0108892D0 (en) The treatment of respiratory diseases
AU1324002A (en) Treatment of demyelinating diseases
AU2002365654A8 (en) Treatment of diseases via the skin
TW503698U (en) Case dedicated for treatment of animals
SI1341542T1 (sl) Indanilni derivati za zdravljenje bolezni dihalnih poti
GB0224330D0 (en) Treatment of respiratory disorders
GB0211414D0 (en) Treatment of respiratory disorders

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)